The SuperFluids™ critical fluid extraction and fractionation (CXF) process enhances the drug discovery process – firstly, by rapidly producing partially-purified natural product molecules and secondly, by enhancing the probability of "clean" hits. CXF produces a unique spectrum of secondary metabolites, reduces interference from nuisance compounds and minimizes background noise in sensitive molecular assays. The CXF technology (process and apparatus) has been automated for high throughput fractionation of biologically-derived materials such as marine organisms and terrestrial plants. Aphios is currently utilizing this platform technology to develop novel antiviral and anticancer therapeutics from marine organisms and terrestrial plants.
Research leading to the development of this U.S. Patent was partially funded by SBIR grants from the National Science Foundation, and an Advance Technology Program (ATP) Cooperative Agreement award from the National Institute of Standards and Technology (NIST), U.S. Department of Commerce.
Aphios Corporation is a biopharmaceutical company that is developing enhanced natural therapeutics for health maintenance and the treatment of human diseases with a focus on infectious diseases, cancer and quality-of-life medicines. Aphios' product pipeline includes therapeutics from medicinal plants and marine organisms, and improved drug delivery formulations of small anticancer molecules and large protein macromolecules that are crucial to the functioning of the human genome.
